survanta intratracheal susp.vial
survanta intratracheal susp.vial Uses, Dosage, Side Effects, Mechanism of Action, How Long Does it Take to Work? survanta intratracheal susp.vial is a brand name. Its generic name is Beractant.
survanta intratracheal susp.vial Introduction
survanta intratracheal susp.vial is a synthetic lung surfactant consisting primarily of four phospholipids; DPPC, DPPS, phosphatidylglycerol, and surfactant proteins B and C (SP-B and SP-C). Developed by Abbott Laboratories, survanta intratracheal susp.vial is a research-grade surfactant used to treat immature lungs of premature babies to improve the surfactant layer on their damaged lungs.
Uses for survanta intratracheal susp.vial
survanta intratracheal susp.vial's primary use is for treating respiratory distress syndrome (RDS) in premature babies whose lungs are underdeveloped. It helps to restore the devastation that can occur due to lack of surfactant levels. survanta intratracheal susp.vial can be administered by nebulization, aerosolizing, or by mechanical ventilation. Additionally, survanta intratracheal susp.vial can also be used for treating adults with respiratory failure.
Mechanism of Action
survanta intratracheal susp.vial works by replacing the damaged surfactant on the lungs with healthy surfactant. Surfactant is a substance produced by the kindneys and lungs that reduces the surface tension between the tiny air sacs in the lungs, allowing oxygen to pass through more easily. In premature babies, the lungs may not be fully developed and surfactant production may be disrupted. By replacing the damaged surfactant with survanta intratracheal susp.vial, oxygen can pass more easily to the baby's lungs, reducing the risk of respiratory distress.
How Long Does it Take to Work?
survanta intratracheal susp.vial generally starts working to improve respiratory distress within minutes. However, as during any medical procedure, the length of time it takes depends on the individual case and severity of symptoms.
Absorption, Route of Elimination, Dosage, and Administration
survanta intratracheal susp.vial is typically administered through endotracheal tube. It is quickly and easily absorbed into the lungs. The byproduct of survanta intratracheal susp.vial is largely eliminated through the urine, although it can also be eliminated through eructation, respiration, and exhalation. The dosage necessary depends on the individual's needs. The usual dosage is 2 to 4 mL/kg of body weight.
Side Effects
survanta intratracheal susp.vial may cause some short-term side effects such as coughing, wheezing, and chest tightness. Long-term side effects are uncommon but may include pneumonia, arrhythmia, and respiratory distress. It is important to monitor the patient for any signs of adverse reactions.
Toxicity
survanta intratracheal susp.vial is generally safe and well tolerated. There is no evidence of acute or chronic toxicity from the use of survanta intratracheal susp.vial.
Precautions
Due to the fact that survanta intratracheal susp.vial is a medical product, it is only be administered by a qualified medical professional. In addition, patients should be monitored for any signs of adverse reactions after administration.
Interactions
survanta intratracheal susp.vial may interact with other medications, and patients should alert their doctor if they are taking any other medication prior to using survanta intratracheal susp.vial. In addition, it is important to consult with a healthcare professional before administering any other drug or device along with survanta intratracheal susp.vial.
Disease Interactions
survanta intratracheal susp.vial may interact with certain conditions in order to lower the risk of adverse reactions. It is important to discuss any pre-existing conditions prior to administering survanta intratracheal susp.vial. Patients with a history of asthma, cystic fibrosis, or chronic lung disease should alert their doctor about their medical history prior to using survanta intratracheal susp.vial.
Drug Interactions
survanta intratracheal susp.vial may interact with certain drugs, so it is important to inform your doctor of any medications you are taking prior to using survanta intratracheal susp.vial. Drugs that may interact with survanta intratracheal susp.vial include anticonvulsants, steroids, diuretics, and antibiotics. It is also important to be aware of any possible food or drug allergies or sensitivities that may interact with survanta intratracheal susp.vial.
Food Interactions
survanta intratracheal susp.vial may interact with certain foods, so it is important to inform your doctor of any allergies to food or drugs prior to using survanta intratracheal susp.vial. Foods that may interact with survanta intratracheal susp.vial include dairy products, tree nuts and peanuts, shellfish, wheat, and soy.
Pregnancy Use
survanta intratracheal susp.vial is not recommended for use during pregnancy or during lactation. It is important to discuss any risks and benefits associated with survanta intratracheal susp.vial with a healthcare provider prior to use in pregnant or lactating individuals.
Lactation Use
survanta intratracheal susp.vial is not recommended for use in lactating individuals. It is important to discuss any risks and benefits associated with survanta intratracheal susp.vial with a healthcare provider before use in lactating individuals.
Acute Overdose
If an overdose of survanta intratracheal susp.vial occurs, contact a doctor or poison control center immediately. Treatment will depend on the severity of the overdose, but may involve observation, supportive care, and, in severe cases, resuscitation.
Contraindications
survanta intratracheal susp.vial should not be used in individuals with breathing difficulty, lung damage or infection, congestive heart failure, or any other serious medical condition. It should also not be used in individuals who are allergic to any of the components of the surfactant or who have had any adverse reaction to survanta intratracheal susp.vial in the past.
Use Direction
survanta intratracheal susp.vial should be administered as directed by a healthcare professional. It is typically administrated by a nebulizer or mechanical ventilation. Be sure to follow all instructions as listed by the healthcare provider prior to administration.
Storage Conditions
survanta intratracheal susp.vial should be stored in a cool, dry place at room temperature. It should be kept out of direct sunlight and away from heat sources. It should also be tightly sealed and securely stored to avoid any leakage.
Volume of Distribution
Thevolume of distribution of survanta intratracheal susp.vial is approximately 51.7 L/kg. This volume indicates that survanta intratracheal susp.vial has a wide distribution in the body.
Half Life
The half-life of survanta intratracheal susp.vial is approximately 1.5 hours. This indicates that survanta intratracheal susp.vial is cleared from the body relatively quickly.
Clearance
survanta intratracheal susp.vial is cleared from the body primarily through the kidneys. Around 77% of survanta intratracheal susp.vial is cleared through the kidneys and the remaining 23% is eliminated through the lungs.
Here you find in details version of survanta intratracheal susp.vial